Related Experiment Video
Updated: May 11, 2025

Determination of the Absorption, Translocation, and Distribution of Imidacloprid in Wheat
Published on: April 28, 2023
Human plasma protein bindings of neonicotinoid insecticides and metabolites
Kumiko Taira1, Yoshinori Ikenaka2, Jean-Marc Bonmatin3
1Department of Anesthesiology, Adachi Medical Center, Tokyo Women's Medical University, 4-33-1, Kohoku, Adachi-ku, Tokyo, 123-8558, Japan. tfsp.phwg@gmail.com.
Abstract:
Neonicotinoid insecticides (neonicotinoids) are widely used in agriculture, forestry and public health in the world. Environmental exposure to neonicotinoids has been increasing due to their continuous uses. Neonicotinoids act as agonists, antagonists, or modulators of acetylcholine receptors and have adverse effects on non-target species, such as invertebrates, amphibians, reptiles, birds, microbes and mammals. Although there is concern about their adverse effects on ecosystem services and their potential effects on human health, their xenobiotic kinetics and dynamics in humans are not understood well. In this study, we determined a xenobiotic kinetic parameter, plasma protein bindings (PPBs) of 7 neonicotinoids and 18 metabolites with human plasma using a Rapid Equilibrium Dialysis (RED) device and liquid chromatography-tandem mass spectrometry (LC-MS/MS), and compared their PPBs with their physicochemical properties. 6-chloronicotinic acid (6-CNA) exhibited the highest PPB (86.4%), followed by imidacloprid-olefin (86.3%) in human plasma. Their PPBs are much higher than that of the parent compound, imidacloprid (27.5%). The PPBs of neonicotinoids and metabolites are not related to their lipophilicity determined by reversed-phase LC. The results shed light on the behavior of environmentally exposed neonicotinoids and metabolites and warrant further research on their xenobiotic kinetics and dynamics in humans.
Related Concept Videos
Drug Distribution: Plasma Protein Binding
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...

